Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 8;17(6):1447-1547.
doi: 10.5114/aoms/141941. eCollection 2021.

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

Maciej Banach  1   2   3 , Paweł Burchardt  4   5 , Krzysztof Chlebus  6 , Piotr Dobrowolski  7 , Dariusz Dudek  8 , Krzysztof Dyrbuś  9 , Mariusz Gąsior  9 , Piotr Jankowski  10   11 , Jacek Jóźwiak  12 , Longina Kłosiewicz-Latoszek  13 , Irina Kowalska  14 , Maciej Małecki  15 , Aleksander Prejbisz  7 , Michał Rakowski  16 , Jacek Rysz  17 , Bogdan Solnica  18 , Dariusz Sitkiewicz  19 , Grażyna Sygitowicz  19 , Grażyna Sypniewska  20 , Tomasz Tomasik  21 , Adam Windak  21 , Dorota Zozulińska-Ziółkiewicz  22 , Barbara Cybulska  13
Affiliations

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

Maciej Banach et al. Arch Med Sci. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Maciej Banach has received grant/research support from Amgen, Sanofi, Mylan/Viatris, and has worked as a consultant/received lecture fees from: Amgen, Daichii Sankyo, Esperion, Freia Pharmaceuticals, Herbapol, Kogen, KRKA, Mylan/Viatris, Novo Nordisk, Novartis, Polfarmex, Polpharma, Sanofi, Teva, Zentiva; works as CMO in Nomi Biotech Corporation Ltd.; Dariusz Dudek has received honoraria and grant/research support from: Amgen, Astra Zeneca, Cardinal Health, Gedeon Richter, Sanofi Piotr Jankowski has received honoraria and research grants from: Amgen, Sanofi, Novartis, Servier, Zentiva; Jacek Jóźwiak has received grant/research support from Valeant and has worked as a consultant/received lectures from: Amgen, Boehringer Ingelheim, Teva, Zentiva, Celgene, Servier, Bioton, ALAB; works as ADMO in Synexus; Irina Kowalska worked as consultant/received lecture fees from: Ascensia Diabetes Care, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi; Bogdan Solnica has received lecture fees from Abbott Laboratories Poland, Argenta, Beckman Coulter, Euroimmun, Roche Diagnostics, Siemens Healthcare; Tomasz Tomasik declares cooperation with Boehringer Ingelheim, Novartis, Shire, Biofarm, Eli Lilly, and AstraZeneca; Dorota Zozulińska-Ziółkiewicz has received grant/research support from Novo Nordisk and worked as a consultant/received lecture fees from: Abbott, Astra Zeneca, Bioton, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Mundipharma, Novo Nordisk, Roche, Sanofi, Zentiva; other experts report no conflict of interest.

Figures

Figure 1
Figure 1
Mean values of lipid profile parameters in the LIPIDOGRAM2004 and LIPIDOGRAM2006 studies
Figure 2
Figure 2
SCORE tables calibrated for the Polish population (Pol-SCORE 2015) [48]. Numbers in the table represent 10-year risk of cardiovascular death
Figure 3
Figure 3
Frequency of prescription of specific doses of atorvastatin and rosuvastatin in Poland (2017April 2021; data based on the IMS)
Figure 4
Figure 4
Prescription of rosuvastatin in combination with ezetimibe (fixed combination) in Poland between May 2019 and April 2021 (based on the IMS)
Figure 5
Figure 5
Recommendations for low-risk patients with persistently elevated LDL cholesterol concentration (modified according to the ILEP 2020 recommendations [2])
Figure 6
Figure 6
Algorithm for intensive lipid-lowering combination therapy in patients with ACS at very high or extreme risk
Figure 7
Figure 7
Algorithm for intensive lipid-lowering combination therapy in patients at extreme cardiovascular risk
Figure 8
Figure 8
Algorithm for lipid-lowering therapy in statin-intolerant patients with ACS
Figure 9
Figure 9
Algorithm for intensive lipid-lowering combination therapy in patients with ACS optimally treated before hospitalization
Figure 10
Figure 10
Possible combinations of individual agents used in treatment of lipid disorders
Figure 11
Figure 11
Recommendations on treatment of hypertriglyceridaemia (adapted and modified, based on the EAS Expert Opinion 2021 [140])
Figure 12
Figure 12
Detailed recommendations for management of patients with statin intolerance
Figure 13
Figure 13
Key reasons for non-adherence (modified based on [428])
See this image and copyright information in PMC

References

    1. Soran H, Adam S, Mohammad JB, et al. Hypercholesterolaemia – practical information for non-specialists. Arch Med Sci. 2018;14:1–21. - PMC - PubMed
    1. Penson PE, Pirro M, Banach M. LDL-C: lower is better for longer-even at low risk. BMC Med. 2020;18:320. - PMC - PubMed
    1. Ling JZJ, Montvida O, Khunti K, Zhang AL, Xue CC, Paul SK. Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: real-world evidence from primary care. Diabetes Obes Metab. 2021;23:1518–31. - PubMed
    1. Zdrojewski T, Solnica B, Cybulska B, et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016;74:213–23. - PubMed
    1. Banach M, Penson PE. Cellular senescence, telomeres, and cardiovascular risk in familial hypercholesterolaemia. Eur J Prev Cardiol. 2020 Dec 30;:zwaa145. doi: 10.1093/eurjpc/zwaa145. - DOI - PubMed